alarm-ringing ambulance angle2 archive arrow-down arrow-left arrow-right arrow-up at-sign baby baby2 bag binoculars book-open book2 bookmark2 bubble calendar-check calendar-empty camera2 cart chart-growth check chevron-down chevron-left chevron-right chevron-up circle-minus circle city clapboard-play clipboard-empty clipboard-text clock clock2 cloud-download cloud-windy cloud clubs cog cross crown cube youtube diamond4 diamonds drop-crossed drop2 earth ellipsis envelope-open envelope exclamation eye-dropper eye facebook file-empty fire flag2 flare foursquare gift glasses google graph hammer-wrench heart-pulse heart home instagram joystick lamp layers lifebuoy link linkedin list lock magic-wand map-marker map medal-empty menu microscope minus moon mustache-glasses paper-plane paperclip papers pen pencil pie-chart pinterest plus-circle plus power printer pushpin question rain reading receipt recycle reminder sad shield-check smartphone smile soccer spades speed-medium spotlights star-empty star-half star store sun-glasses sun tag telephone thumbs-down thumbs-up tree tumblr twitter user users wheelchair write yelp youtube

Research suggests overexpectations about drug therapy may cause some patients with AMD to stop treatment

MedPage Today (5/7, Susman) reported that, according to a study presented at a vision research conference, “expecting too much from injections of drugs such as bevacizumab (Avastin) may be one reason patients with age-related macular degeneration (AMD) give up on therapy.” For the study, researchers from the Hospital Regional de Sao Jose in Santa Catarina, Brazil “reported on treatment with bevacizumab in 82 patients with” AMD, “24 of whom decided to interrupt the therapy.” The team was “able to determine the causes for interruption in 19 of those individuals.” Specifically, “eight of the patients thought that visual results were poor,” and “five complained about lack of information about the need for follow-up visits.” Meanwhile, “three patients stopped the treatments because of comorbidities, and the other three mentioned difficulties in booking appointments or traveling for treatment.” The investigators “noted that 14 of the patients who discontinued treatment actually had shown some improvement in visual acuity,” but “the improvement that was expected by the patients was not achieved.” The authors concluded that patients need to know that “vision improvement” will not “happen in everyone.”